Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

This study is testing a combination treatment approach for advanced colorectal cancer that has stopped responding to first-line therapy. It combines a standard second-line drug (TAS-102, also called trifluridine/tipiracil) with bevacizumab (a drug that blocks tumor blood vessel growth) and local treatments aimed at specific tumor sites. **You may be eligible if...** - You have unresectable (cannot be surgically removed) colorectal cancer confirmed by biopsy or cytology - Your cancer has progressed on first-line standard therapy and you need second-line treatment - You have at least one measurable tumor on imaging - Your general health score is 0–1 (ECOG) and life expectancy is at least 3 months - Your organ function (blood counts, kidney, liver) meets required levels **You may NOT be eligible if...** - You have previously been treated with TAS-102 - You are pregnant or breastfeeding - You have unresolved side effects (Grade 2 or higher) from prior treatment - You have a bleeding disorder or are on full-dose anticoagulants - You have had a serious cardiovascular event recently Talk to your doctor to see if this trial is right for you.